ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection

Lu, Mengjia; Yao, Weitong; Li, Yujun*; Ma, Danting; Zhang, Zhaoyong; Wang, Haimin; Tang, Xiaojuan; Wang, Yanqun; Li, Chao; Cheng, Dechun; Lin, Hua; Yin, Yandong*; Zhao, Jincun*; Zhong, Guocai*广州医学院; 北京大学; 1; i
Microbiology Spectrum2023-8-17DOI: 10.1128/spectrum.01100-23
7阅读
引用收藏
分享

摘要

As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have been causing increasingly serious drug resistance problem, development of broadly effective and hard-to-escape anti-SARS-CoV-2 agents is an urgent need. Here, we describe further development and characterization of two SARS-CoV-2 receptor decoy proteins, ACE2-Ig-95 and ACE2-Ig-105/106. We found that both proteins had potent and robust in vitro neutralization activities against diverse SARS-CoV-2 variants, including BQ.1 and XBB.1, that are resistant to most clinically used monoclonal antibodies. In a stringent lethal SARS-CoV-2 infection mouse model, both proteins lowered the lung viral load by up to similar to 1,000-fold, prevented the emergence of clinical signs in >75% animals, and increased the animal survival rate from 0% (untreated) to >87.5% (treated). These results demonstrate that both proteins are good drug candidates for protecting animals from severe COVID-19. In a head-to-head comparison of these two proteins with five previously described ACE2-Ig constructs, we found that two constructs, each carrying five surface mutations in the ACE2 region, had partial loss of neutralization potency against three SARS-CoV-2 variants. These data suggest that extensively mutating ACE2 residues near the receptor binding domain (RBD)-binding interface should be avoided or performed with extra caution. Furthermore, we found that both ACE2-Ig-95 and ACE2-Ig-105/106 could be produced to the level of grams per liter, demonstrating the developability of them as biologic drug candidates. Stress condition stability testing of them further suggests that more studies are required in the future to improve the stability of these proteins. These studies provide useful insight into critical factors for engineering and preclinical development of ACE2 decoys as broadly effective therapeutics against diverse ACE2-utilizing coronaviruses. @@@ IMPORTANCE Engineering soluble ACE2 proteins that function as a receptor decoy to block SARS-CoV-2 infection is a very attractive approach to creating broadly effective and hard-to-escape anti-SARS-CoV-2 agents. This article describes development of two antibody-like soluble ACE2 proteins that broadly block diverse SARS-CoV-2 variants, including Omicron. In a stringent COVID-19 mouse model, both proteins successfully protected >87.5% animals from lethal SARS-CoV-2 infection. In addition, a head-to-head comparison of the two constructs developed in this study with five previously described ACE2 decoy constructs was performed here. Two previously described constructs with relatively more ACE2 surface mutations were found with less robust neutralization activities against diverse SARS-CoV-2 variants. Furthermore, the developability of the two proteins as biologic drug candidates was also assessed here. This study provides two broad anti-SARS-CoV-2 drug candidates and useful insight into critical factors for engineering and preclinical development of ACE2 decoys as broadly effective therapeutics against diverse ACE2-utilizing coronaviruses.

学科与关键词

关键词
SARS-CoV-2variant of concernOmicronACE2receptor decoyACE2-Igmouse modellethal infection
相关
加载中…
  • Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
    Zhang, Zhaoyong; Zeng, Eric; Zhang, Lu; Wang, Weiming; Jin, Yingkang; Sun, Jiye; Huang, Shuxiang; Yin, Wenguang; Dai, Jun; Zhuang, Zhen; Chen, Zhao; Sun, Jing; Zhu, Airu; Li, Fang; Cao, Weitao; Li, Xiaobo; Shi, Yongxia; Gan, Mian; Zhang, Shengnan; Wei, Peilan; Huang, Jicheng; Zhong, Nanshan; Zhong, Guocai*; Zhao, Jingxian*; Wang, Yanqun*; Shao, Weihui*; Zhao, Jincun*Cell Discovery, 2021, 7(1): 65.被引 40
  • Potential use of the S-protein-Angiotensin converting enzyme 2 binding pathway in the treatment of coronavirus disease 2019
    Feng, Long; Fu, Shihui; Zhang, Pei; Zhang, Yujie; Zhao, Yali*; Yao, Yao*; Luo, Leiming*; Ping, Ping*Frontiers in Public Health, 2022, 10: 1050034.
  • Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses
    Wang, Yingdan; Liu, Meiqin; Shen, Yaping; Ma, Yunping; Li, Xiang; Zhang, Yuanyuan; Liu, Mei; Yang, Xing-Lou; Chen, Jun; Yan, Renhong; Luan, Die; Wang, Yanqun; Chen, Ying; Wang, Qimin; Lin, Haofeng; Li, Yaning; Wu, Kaiyue; Zhu, Tongyu; Zhao, Jincun; Lu, Hongzhou; Wen, Yumei; Jiang, Shibo; Wu, Fan; Zhou, Qiang; Shi, Zheng-Li; Huang, JingheCell Discovery, 2022, 8(1): 36.被引 18
查看全部 →

发表信息

论文状态
公开发表
期刊
Microbiology Spectrum
发表日期
2023-08-17
卷期
第 11 卷, 第 4 期
DOI
10.1128/spectrum.01100-23
成果收录
SCIE
资助标注
Shenzhen Bay Laboratory Major Program [S201101001-2]; Shenzhen Bay Laboratory Key COVID-19 Program grant [S211410002]

作者

  • L

    Lu, Mengjia (第一作者)

    peking univ

  • Y

    Yao, Weitong

查看全部 14 位作者收起作者
  • L

    Li, Yujun (通讯)

    shenzhen univ

  • M

    Ma, Danting

    i · tianjin med univ

  • Z

    Zhang, Zhaoyong

    1 · guangzhou med univ

  • W

    Wang, Haimin

  • T

    Tang, Xiaojuan

    peking univ

  • W

    Wang, Yanqun

    1 · guangzhou med univ

  • L

    Li, Chao

  • C

    Cheng, Dechun

  • L

    Lin, Hua

    fujian normal univ

  • Y

    Yin, Yandong (通讯)

    peking univ

  • Z

    Zhao, Jincun (通讯)

    1 · guangzhou med univ

  • Z

    Zhong, Guocai (通讯)

    peking univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417